Clinical, neuroimaging and biochemical findings in patients and patient fibroblasts expressing ten novel GFM1 mutations

Hum Mutat. 2020 Feb;41(2):397-402. doi: 10.1002/humu.23937. Epub 2019 Nov 11.

Abstract

Pathogenic GFM1 variants have been linked to neurological phenotypes with or without liver involvement, but only a few cases have been reported in the literature. Here, we report clinical, biochemical, and neuroimaging findings from nine unrelated children carrying GFM1 variants, 10 of which were not previously reported. All patients presented with neurological involvement-mainly axial hypotonia and dystonia during the neonatal period-with five diagnosed with West syndrome; two children had liver involvement with cytolysis episodes or hepatic failure. While two patients died in infancy, six exhibited a stable clinical course. Brain magnetic resonance imaging showed the involvement of basal ganglia, brainstem, and periventricular white matter. Mutant EFG1 and OXPHOS proteins were decreased in patient's fibroblasts consistent with impaired mitochondrial translation. Thus, we expand the genetic spectrum of GFM1-linked disease and provide detailed clinical profiles of the patients that will improve the diagnostic success for other patients carrying GFM1 mutations.

Keywords: EFG1; GFM1; OXPHOS; mitochondrial diseases; mitochondrial translation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Brain / diagnostic imaging
  • Brain / pathology
  • Databases, Genetic
  • Female
  • Fibroblasts / metabolism*
  • Gene Expression Regulation*
  • Genetic Association Studies* / methods
  • Genetic Predisposition to Disease*
  • Humans
  • Image Processing, Computer-Assisted
  • Magnetic Resonance Imaging
  • Male
  • Mitochondria / genetics
  • Mitochondrial Proteins / genetics*
  • Mutation*
  • Neuroimaging* / methods
  • Pedigree
  • Peptide Elongation Factor G / genetics*

Substances

  • GFM1 protein, human
  • Mitochondrial Proteins
  • Peptide Elongation Factor G